Phase I, Multicenter, Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Lurbinectedin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors PharmaMar
- 09 Aug 2018 Results of pooled data from six phase I and three phase II trials with lurbinectedin, were published in the Clinical Pharmacokinetics.
- 13 Jun 2011 Actual end date changed from 24 Nov 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 26 Nov 2010 Status changed from recruiting to completed as stated in a PharmaMar media release dated 24 November 2010.